Skip to content

Gustavo C Medeiros

5 papers in the library · 101 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

Synaptic priming: A framework for pharmacotherapy in depression.

Neuron November 19, 2025 Kyle A Brown, Musa I Ajibola, Gustavo C Medeiros et al. 6 citations

Recent antidepressant drug development focuses on a next generation of drugs to rapidly relieve symptoms. Yet, how ketamine, the prototype rapid-acting antidepressant, maintains symptom relief days after drug elimination, and how repeated doses sustain longer-lasting therapeutic effects, remains unclear. Derived from elements of metaplasticity (synaptic priming), this review discusses a...

High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression.

Biological Psychiatry Global Open Science July 1, 2025 Stephen A Murata, Zachary B Madaj, Colt D Capan et al. 1 citation

Treatment-resistant depression (TRD) remains a challenge, but intravenous racemic ketamine offers rapid antidepressant effects. Reliable biomarkers are needed. In this study, we examined kynurenine pathway metabolites and inflammatory cytokines as predictors of ketamine response. The Bio-K study was a multicenter, open-label trial of 74 patients with TRD who received 3 ketamine infusions over...

Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

Journal of Affective Disorders March 15, 2025 Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros et al. 24 citations

Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a...

Personalized use of ketamine and esketamine for treatment-resistant depression.

Translational Psychiatry November 29, 2024 Gustavo C Medeiros, Isabella Demo, Fernando S Goes et al. 32 citations

A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resistant depression (TRD). Intravenous (R,S)-ketamine (ketamine) and intranasal (S)-ketamine (esketamine) are rapid-acting antidepressants that can effectively treat TRD. However, there is variability in response to ketamine/esketamine, and a personalized approach to their use...

Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.

The lancet. Psychiatry October 1, 2023 Gustavo C Medeiros, Malcolm Matheson, Isabella Demo et al. 38 citations

Ketamine is an effective antidepressant, but there is substantial variability in patient response and the precise mechanism of action is unclear. Neuroimaging can provide predictive and mechanistic insights, but findings are limited by small sample sizes. This systematic review covers neuroimaging studies investigating baseline (pre-treatment) and longitudinal (post-treatment) biomarkers of...